Cargando…

Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2

VEGFR-2, the subtype receptor tyrosine kinase (RTK) responsible for angiogenesis, is expressed in various cancer cells. Thus, VEGFER-2 inhibition is an efficient approach for the discovery of new anticancer agents. Accordingly, a new set of nicotinamide derivatives were designed and synthesized to b...

Descripción completa

Detalles Bibliográficos
Autores principales: Yousef, Reda G., Eldehna, Wagdy M., Elwan, Alaa, Abdelaziz, Abdelaziz S., Mehany, Ahmed B. M., Gobaara, Ibraheem M. M., Alsfouk, Bshra A., Elkaeed, Eslam B., Metwaly, Ahmed M., Eissa, Ibrahim H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268560/
https://www.ncbi.nlm.nih.gov/pubmed/35807326
http://dx.doi.org/10.3390/molecules27134079
_version_ 1784744014629568512
author Yousef, Reda G.
Eldehna, Wagdy M.
Elwan, Alaa
Abdelaziz, Abdelaziz S.
Mehany, Ahmed B. M.
Gobaara, Ibraheem M. M.
Alsfouk, Bshra A.
Elkaeed, Eslam B.
Metwaly, Ahmed M.
Eissa, Ibrahim H.
author_facet Yousef, Reda G.
Eldehna, Wagdy M.
Elwan, Alaa
Abdelaziz, Abdelaziz S.
Mehany, Ahmed B. M.
Gobaara, Ibraheem M. M.
Alsfouk, Bshra A.
Elkaeed, Eslam B.
Metwaly, Ahmed M.
Eissa, Ibrahim H.
author_sort Yousef, Reda G.
collection PubMed
description VEGFR-2, the subtype receptor tyrosine kinase (RTK) responsible for angiogenesis, is expressed in various cancer cells. Thus, VEGFER-2 inhibition is an efficient approach for the discovery of new anticancer agents. Accordingly, a new set of nicotinamide derivatives were designed and synthesized to be VEGFR-2 inhibitors. The chemical structures were confirmed using IR, (1)H-NMR, and (13)C-NMR spectroscopy. The obtained compounds were examined for their anti-proliferative activities against the human cancer cell lines (HCT-116 and HepG2). VEGFR-2 inhibitory activities were determined for the titled compounds. Compound 8 exhibited the strongest anti-proliferative activities with IC(50) values of 5.4 and 7.1 µM against HCT-116 and HepG2, respectively. Interestingly, compound 8 was the most potent VEGFR-2 inhibitor with an IC(50) value of 77.02 nM (compare to sorafenib: IC(50) = 53.65 nM). Treatment of HCT-116 cells with compound 8 produced arrest of the cell cycle at the G0–G1 phase and a total apoptosis increase from 3.05 to 19.82%—6.5-fold in comparison to the negative control. In addition, compound 8 caused significant increases in the expression levels of caspase-8 (9.4-fold) and Bax (9.2-fold), and a significant decrease in the Bcl-2 expression level (3-fold). The effects of compound 8 on the levels of the immunomodulatory proteins (TNF-α and IL-6) were examined. There was a marked decrease in the level of TNF-α (92.37%) compared to the control (82.47%) and a non-significant reduction in the level of IL-6. In silico docking, molecular dynamics simulations, and MM-PBSA studies revealed the high affinity, the correct binding, and the optimum dynamics of compound 8 inside the active site of VEGFR-2. Finally, in silico ADMET and toxicity studies indicated acceptable values of drug-likeness. In conclusion, compound 8 has emerged as a promising anti-proliferative agent targeting VEGFR-2 with significant apoptotic and immunomodulatory effects.
format Online
Article
Text
id pubmed-9268560
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92685602022-07-09 Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2 Yousef, Reda G. Eldehna, Wagdy M. Elwan, Alaa Abdelaziz, Abdelaziz S. Mehany, Ahmed B. M. Gobaara, Ibraheem M. M. Alsfouk, Bshra A. Elkaeed, Eslam B. Metwaly, Ahmed M. Eissa, Ibrahim H. Molecules Article VEGFR-2, the subtype receptor tyrosine kinase (RTK) responsible for angiogenesis, is expressed in various cancer cells. Thus, VEGFER-2 inhibition is an efficient approach for the discovery of new anticancer agents. Accordingly, a new set of nicotinamide derivatives were designed and synthesized to be VEGFR-2 inhibitors. The chemical structures were confirmed using IR, (1)H-NMR, and (13)C-NMR spectroscopy. The obtained compounds were examined for their anti-proliferative activities against the human cancer cell lines (HCT-116 and HepG2). VEGFR-2 inhibitory activities were determined for the titled compounds. Compound 8 exhibited the strongest anti-proliferative activities with IC(50) values of 5.4 and 7.1 µM against HCT-116 and HepG2, respectively. Interestingly, compound 8 was the most potent VEGFR-2 inhibitor with an IC(50) value of 77.02 nM (compare to sorafenib: IC(50) = 53.65 nM). Treatment of HCT-116 cells with compound 8 produced arrest of the cell cycle at the G0–G1 phase and a total apoptosis increase from 3.05 to 19.82%—6.5-fold in comparison to the negative control. In addition, compound 8 caused significant increases in the expression levels of caspase-8 (9.4-fold) and Bax (9.2-fold), and a significant decrease in the Bcl-2 expression level (3-fold). The effects of compound 8 on the levels of the immunomodulatory proteins (TNF-α and IL-6) were examined. There was a marked decrease in the level of TNF-α (92.37%) compared to the control (82.47%) and a non-significant reduction in the level of IL-6. In silico docking, molecular dynamics simulations, and MM-PBSA studies revealed the high affinity, the correct binding, and the optimum dynamics of compound 8 inside the active site of VEGFR-2. Finally, in silico ADMET and toxicity studies indicated acceptable values of drug-likeness. In conclusion, compound 8 has emerged as a promising anti-proliferative agent targeting VEGFR-2 with significant apoptotic and immunomodulatory effects. MDPI 2022-06-24 /pmc/articles/PMC9268560/ /pubmed/35807326 http://dx.doi.org/10.3390/molecules27134079 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yousef, Reda G.
Eldehna, Wagdy M.
Elwan, Alaa
Abdelaziz, Abdelaziz S.
Mehany, Ahmed B. M.
Gobaara, Ibraheem M. M.
Alsfouk, Bshra A.
Elkaeed, Eslam B.
Metwaly, Ahmed M.
Eissa, Ibrahim H.
Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2
title Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2
title_full Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2
title_fullStr Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2
title_full_unstemmed Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2
title_short Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2
title_sort design, synthesis, in silico and in vitro studies of new immunomodulatory anticancer nicotinamide derivatives targeting vegfr-2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268560/
https://www.ncbi.nlm.nih.gov/pubmed/35807326
http://dx.doi.org/10.3390/molecules27134079
work_keys_str_mv AT yousefredag designsynthesisinsilicoandinvitrostudiesofnewimmunomodulatoryanticancernicotinamidederivativestargetingvegfr2
AT eldehnawagdym designsynthesisinsilicoandinvitrostudiesofnewimmunomodulatoryanticancernicotinamidederivativestargetingvegfr2
AT elwanalaa designsynthesisinsilicoandinvitrostudiesofnewimmunomodulatoryanticancernicotinamidederivativestargetingvegfr2
AT abdelazizabdelazizs designsynthesisinsilicoandinvitrostudiesofnewimmunomodulatoryanticancernicotinamidederivativestargetingvegfr2
AT mehanyahmedbm designsynthesisinsilicoandinvitrostudiesofnewimmunomodulatoryanticancernicotinamidederivativestargetingvegfr2
AT gobaaraibraheemmm designsynthesisinsilicoandinvitrostudiesofnewimmunomodulatoryanticancernicotinamidederivativestargetingvegfr2
AT alsfoukbshraa designsynthesisinsilicoandinvitrostudiesofnewimmunomodulatoryanticancernicotinamidederivativestargetingvegfr2
AT elkaeedeslamb designsynthesisinsilicoandinvitrostudiesofnewimmunomodulatoryanticancernicotinamidederivativestargetingvegfr2
AT metwalyahmedm designsynthesisinsilicoandinvitrostudiesofnewimmunomodulatoryanticancernicotinamidederivativestargetingvegfr2
AT eissaibrahimh designsynthesisinsilicoandinvitrostudiesofnewimmunomodulatoryanticancernicotinamidederivativestargetingvegfr2